KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.

Laura C Coates, Ricardo Blanco, Frank Behrens, Alexis Ogdie, Filip Van den Bosch, Roberto Ranza, Yael Klionsky, Ahmed M Soliman, Michael Chen, Derek Coombs, Linyu Shi, Jamie R Urbanik, Thomas Iyile, Ralph Lippe, Laure Gossec

RMD Open 11(3) e005522

PMID40854810
PMCIDPMC12382576
DOI10.1136/rmdopen-2025-005522
发表日期2025-08-25
入排依据:未发现恶性肿瘤人群证据。
已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 2 张未列出。
摘要

摘要

OBJECTIVE: To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA). METHODS: This post hoc analysis primarily used data from the phase 3 KEEPsAKE 1 trial of adult patients with PsA, with data from KEEPsAKE 2 pooled for prespecified outcomes. Outcomes measuring risankizumab efficacy across key GRAPPA-recognised domains of PsA (peripheral arthritis, enthesitis, dactylitis, skin and nail psoriasis, axial disease) and PsA-related conditions such as inflammatory bowel disease (IBD) and uveitis were assessed over 100 weeks of treatment (~2 years). Statistical approaches included non-responder imputation (as-observed with imputation) for categorical variables and mixed-effect model for repeated measures for continuous variables including as-observed measurements at all visits. PsA-related conditions were evaluated via adverse events through 100 weeks. RESULTS: Overall, in KEEPsAKE 1 and KEEPsAKE 2, 412/483 (85.3%) and 181/224 (80.8%) of patients randomised to risankizumab completed treatment to week 100. Risankizumab demonstrated efficacy across all GRAPPA-defined domains through 100 weeks, including swollen and tender joint counts, enthesitis, dactylitis, skin and nail outcomes, and axial disease. In KEEPsAKE 1, 42.4% of patients had achieved a Disease Activity in Psoriatic Arthritis measurement of low disease activity and 62.9% had reached a minimal clinically important difference in pain at week 100. Rates of new onset or flare of IBD and uveitis were low. CONCLUSIONS: Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all GRAPPA disease domains and related conditions.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Distribution of DAPSA disease activity level through week 100 (AO). Data for patients in KEEPsAKE 1 and reported as observed. High is DAPSA>28, moderate is 14
非 KM Figure
Figure 2Figure 2. Achievement of ( A ) MCID in pain a over 100 weeks (NRI-C/NRI-MI), b ( B ) structural non-progression at week 100 (AO) and ( C ) improvement in swollen joint count and tender joint count over 100 weeks (MMRM). Data reported for patients in KEEPsAKE 1. a For patients with a patient’s assessment of pain≥10 at baseline. MCID for patient’s assessment of pain is≥10-point decrease. b Reported by NRI-C at week 24 and by NRI-MI at week 52 and week 100. AO, as observed; MCID, minimal clinically important differences; MMRM, mixed effect model repeated measurement; mTSS, modified Total Sharp Score; NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19; NRI-MI, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 and geopolitical conflict, and all other missing data treated as non-responders; PBO, placebo; PBO/RZB, treatment with placebo to week 24, followed by treatment with risankizumab until week 100; RZB, risankizumab; SJC, swollen joint count; TJC, tender joint count.
非 KM Figure
Figure 3Figure 3. Resolution of ( A ) enthesitis and ( B ) dactylitis over 100 Weeks (NRI-C/NRI-MI). Data pooled for patients in KEEPsAKE 1 and KEEPsAKE 2 and reported by NRI-C at week 24 and by NRI-MI at week 52 and week 100. NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19; NRI-MI, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 and geopolitical conflict, and all other missing data treated as non-responders; PBO, placebo; PBO/RZB, treatment with placebo to week 24, followed by treatment with risankizumab until week 100; RZB, risankizumab.
非 KM Figure
Figure 4Figure 4. Achievement of ( A ) PASI 100 and ( B ) absolute PASI≤1 over 100 weeks (NRI-C/NRI-MI). Data reported for patients with BSA≥3% at baseline in KEEPsAKE 1 by NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 at week 24, and by NRI-MI, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 and geopolitical conflict, and all other missing data treated as non-responders at week 52 and week 100. BSA, body surface area; NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19; NRI-MI, non-responder imputation, multiple imputation; PASI, Psoriasis Area and Severity Index; PBO, placebo; PBO/RZB, treatment with placebo to week 24, followed by treatment with risankizumab until week 100; RZB, risankizumab.
非 KM Figure
Figure 5Figure 5. Improvement in nail psoriasis over 100 weeks (MMRM). Data reported for patients in KEEPsAKE 1 with nail psoriasis at baseline. Data for mNAPSI reported by Mixed Effect Model Repeated Measurement (MMRM) analysis and data for PGA-F reported by NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 at week 24, and by NRI-MI, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 and geopolitical conflict, and all other missing data treated as non-responders at week 52 and week 100. mNAPSI, modified Nail Psoriasis Severity Index; NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19; NRI-MI, non-responder imputation, multiple imputation; PGA-F, Physician’s Global Assessment of Fingernail Psoriasis; PBO, placebo; PBO/RZB, treatment with placebo to week 24, followed by treatment with risankizumab until week 100; RZB, risankizumab.
非 KM Figure
Figure 6Figure 6. Achievement of MCID in BASDAI (NRI-C/NRI-MI) and improvement in BASDAI and ASDAS scores (MMRM). MCID defined as≥1.1-point decrease, and N is based on baseline BASDAI≥1.1. Data pooled for patients with axial involvement at baseline in KEEPsAKE 1 and KEEPsAKE 2. For MCID in BASDAI, data reported by NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 at week 24, and by NRI-MI, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19 and geopolitical conflict, and all other missing data treated as non-responders at week 52 and week 100. For change from baseline in BASDAI, BASDAI spinal pain (question 2) and ASDAS, data is reported by MMRM. ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity; MCID, minimal clinically important differences; MMRM, mixed effect model repeated measurement; NRI-C, non-responder imputation incorporating multiple imputations to handle missing data due to COVID-19; NRI-MI, non-responder imputation, multiple imputation; PBO, placebo; PBO/RZB, treatment with placebo to week 24, followed by treatment with risankizumab until week 100; RZB, risankizumab.
非 KM Figure
Figure 7Figure 7. Overview of EMMs by history. Data pooled for KEEPsAKE 1 and KEEPsAKE 2. EMMs, extra-musculoskeletal manifestations; EAER, exposure-adjusted event rates; IBD, inflammatory bowel disease; PY, patient years; RZB, risankizumab.
非 KM Figure